Ensifentrine/Ensifentrine is a new option for maintenance treatment of chronic obstructive pulmonary disease

In a new review article published today, researchers summarize the clinical trial results that led to the U.S. Food and Drug Administration's approval of a new treatment option for chronic obstructive pulmonary disease (COPD), Ohtuvayre (Ensifentrine) - Ensefentine/Ensifentrine inhalation suspension, and their potential impact on patient care. As an incurable disease, treatment goals for COPD include slowing disease progression, improving symptoms, and minimizing exacerbations.

Current drug options include rescue short-acting bronchodilators, long-actingβ-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and/or inhaled corticosteroids (ICS), with the addition of roflumilast, azithromycin, or dupilumab in some cases. The GOLD guidelines recently acknowledged that esfentrine is a potential add-on therapy for patients with dyspnea despite the use of two long-acting bronchodilators.

Ensifentran was approved by the U.S. Food and Drug Administration on June 26, 2024, for the maintenance treatment of chronic obstructive pulmonary disease. It is a small molecule inhibitor of phosphodiesterase-3 (PDE3) and phosphodiesterase-4 (PDE4). Inhibition of PDE3 and PDE4 increases the concentrations of cyclic adenosine monophosphate and cyclic guanosine monophosphate, leading to airway smooth muscle relaxation and bronchiectasis. As an inhaled treatment option with a novel mechanism of action, ensifentran has the potential to complement the current treatment landscape for COPD.

The researchers conducted a literature search to identifyPhase 2 and 3 randomized controlled clinical trials that focused on the use of ensifen in the treatment of chronic obstructive pulmonary disease. The Phase 2 trial (ClinicalTrials.gov ID: NCT03443414) showed that all doses of ensifentran (0.75-6 mg) evaluated significantly improved lung function compared with placebo. During the study period, patients did not receive concomitant long-acting bronchodilators for chronic obstructive pulmonary disease; however, some patients received ICS at baseline.

The U.S. Food and Drug Administration's approval of ensifentran was based on the phase 3 ENHANCE trial of ensifentran in patients with chronic obstructive pulmonary disease (ENHANCE-1, ClinicalTrials.gov ID: NCT04535986; ENHANCE-2, ClinicalTrials.gov ID: NCT04542057). The trials included a total of 1,553 patients with moderate to severe COPD and were conducted over 24 weeks at 250 centers in 17 countries. The primary endpoint was met, with ensifentran significantly reducing symptoms of chronic obstructive pulmonary disease and improving lung function and quality of life. Ensifentrine reducedThe risk of exacerbation of ENHANCE-2 but not ENHANCE-1 was reduced. At the time of the study, 30% to 44% of participants in the ENHANCE trial were not receiving any baseline maintenance therapy.

Ensifentran is well tolerated; common adverse reactions include back pain, hypertension, and urinary tract infection. Investigators of the ENHANCE trial recommend that caution should be used when treating patients with a history of depression and/or suicidal ideation or behavior because ensifentrine is associated with an increase in psychiatric adverse effects.

Ensifentran may be a viable adjuvant treatment option for patients who may not meet criteria for specific treatment recommendations or who are unable to tolerate other options. Ensifentrol's delivery via a nebulizer also offers advantages over other treatments. Inhaled drugs have a lower incidence of systemic effects and may therefore be preferable to other non-inhaled drugs.

The authors of the review emphasize that the development and approval of ensifantrine for maintenance of COPD is an advance in the care of this patient population and that further studies in patients following guideline-recommended regimens are needed to help clarify the role of ensifantrine in the management of COPD.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html